Table 3 Baseline characteristics of users of DPP-4 inhibitors
Variables | Sitagliptin | Vildagliptin | Teneligliptin | Alogliptin | Linagliptin | p-value |
|---|---|---|---|---|---|---|
n = 879 | n = 253 | n = 260 | n = 237 | n = 180 | ||
Age (years, mean ± SE) | 63.1 ± 0.4 | 64.2 ± 0.8 | 66 ± 0.8 | 63.5 ± 0.8 | 67.2 ± 0.9 | 0.0002* |
Sex (female) | 317 (36.1%) | 79 (31.2%) | 87 (33.5%) | 72 (30.4%) | 58 (32.2%) | 0.3791 |
Medical History | ||||||
Cerebrovascular disease | 24 (50%) | 7 (14.6%) | 7 (14.6%) | 6 (12.5%) | 4 (8.3%) | 0.9963 |
Ischemic heart disease | 74 (8.4%) | 29 (11.5%) | 14 (5.4%) | 29 (12.2%) | 20 (11.1%) | 0.038* |
Dyslipidemia | 95 (10.8%) | 44 (17.4%) | 28 (10.8%) | 27 (11.4%) | 23 (12.8%) | 0.0688 |
Hypertension | 78 (8.9%) | 34 (13.4%) | 38 (14.6%) | 26 (11%) | 34 (18.9%) | 0.0008* |
Medication | ||||||
Antidiabetic drug | 628 (71.4%) | 154 (60.9%) | 115 (44.2%) | 144 (60.8%) | 91 (50.6%) | <.0001* |
Lipid-lowering drug | 377 (42.9%) | 115 (45.5%) | 101 (38.9%) | 127 (53.6%) | 76 (42.2%) | 0.0138* |
Antihypertensive drug | 513 (58.4%) | 156 (61.7%) | 154 (59.2%) | 157 (66.2%) | 114 (63.3%) | 0.2087 |
NASID | 177 (20.1%) | 44 (17.4%) | 54 (20.8%) | 45 (19%) | 33 (18.3%) | 0.8433 |
Steroid | 67 (7.6%) | 21 (8.3%) | 33 (12.7%) | 22 (9.3%) | 22 (12.2%) | 0.0695 |